title: Comparison of Pulmicort pMDI plus Nebuhaler and Pulmicort Turbuhaler in asthmatic patients with dysphonia.
abstract: BACKGROUND
  Dysphonia is a known local adverse effect of inhaled corticosteroids. This symptom was investigated by laryngoscopy and assessment in a voice laboratory. The effects of changing the treatment of patients with dysphonia, reported whilst using the pMDI, to pMDI plus Nebuhaler or Tubuhaler was also assessed.
  
  
  METHODS
  Seventy-two patients reporting dysphonia and taking inhaled steroids from a pMDI entered a 12-week, open, parallel group study. Fifty-one completed the study per protocol; 26 in the Nebuhaler group [21 female, mean age 57 years (22-77)] and 25 in the Turbuhaler group [18 female, mean age 58 years (21-81)]. A dysphonia diary card was completed weekly. Voice laboratory assessments and laryngoscopy were performed on entry and at 12 weeks.
  
  
  RESULTS
  There were no differences in voice laboratory data, laryngoscopic evidence of disordered glottic closure and diary data between the two groups at 12 weeks. At study entry laryngoscopic appearances were normal in almost half the patients. Vocal cord bowing was rarely seen. Glottic closure changed in nine patients during the study period, but there was no correlation with voice symptoms. The trend of symptomatic improvement of voice status in the Turbuhaler group did not correlate with voice laboratory assessments and laryngoscopic evidence of disordered glottic closure. After 4 weeks, 40% of patients using Turbuhaler and 8% in the Nebuhaler group scored their voice status as better (P < 0.02) but there was no significant difference between the two groups at 12 weeks (Turbuhaler 52%, Nebuhaler 23%, P=0.08).
  
  
  CONCLUSIONS
  This study does not support the view that dysphonia in asthmatics inhaling corticosteroids is usually caused by myopathic bowing of the vocal cord muscles.
authors.affiliation: Respiratory Medicine Unit, Western General Hospital, Edinburgh, UK.
authors.forename: G K
authors.initials: GK
authors.lastname: Crompton
authors.forename: R
authors.initials: R
authors.lastname: Sanderson
authors.forename: M H
authors.initials: MH
authors.lastname: Dewar
authors.forename: S P
authors.initials: SP
authors.lastname: Matusiewicz
authors.forename: A C
authors.initials: AC
authors.lastname: Ning
authors.forename: A H
authors.initials: AH
authors.lastname: Jamieson
authors.forename: A
authors.initials: A
authors.lastname: McLean
authors.forename: A P
authors.initials: AP
authors.lastname: Greening
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects*; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D007828:Laryngoscopy; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D014797:Vital Capacity / Q000502:physiology; D014832:Voice Disorders / Q000139:chemically induced*; D014833:Voice Quality / Q000502:physiology
chemical_list: D001993:Bronchodilator Agents; D019819:Budesonide